IONS

Ionis Pharmaceuticals, Inc. Common Stock

71.09

USD

IONS Earnings Reports

Positive Surprise Ratio

IONS beat 28 of 41 last estimates.

68%

Next Report

Date of Next Report

Apr 28, 2026

Estimate for Q1 26 (Revenue/ EPS)

$202.89M

-$0.88

Implied change from Q4 25 (Revenue/ EPS)

-0.05%

-37.59%

Implied change from Q1 25 (Revenue/ EPS)

+53.70%

-5.38%

Ionis Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On Feb 25, 2026, IONS reported earnings of -1.41 USD per share (EPS) for Q4 25, missing the estimate of -1.34 USD, resulting in a -4.63% surprise. Revenue reached 203.00 million, compared to an expected 159.22 million, with a 27.50% difference. The market reacted with a +1.06% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 9 analysts forecast an EPS of -0.88 USD, with revenue projected to reach 202.89 million USD, implying an decrease of -37.59% EPS, and decrease of -0.05% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Guardian Pharmacy Services, Inc.

Report Date

Mar 11, 2026 For Q4 25

Estimate

$0.25

Actual

$0.33

Surprise

+29.41%

Oruka Therapeutics, Inc. Common Stock

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.64

Actual

-$0.45

Surprise

+29.69%

Nektar Therapeutics

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$2.52

Actual

-$1.78

Surprise

+29.47%

Savara Inc.

Report Date

Mar 13, 2026 For Q4 25

Estimate

-$0.12

Actual

-$0.13

Surprise

-8.15%

Lyell Immunopharma, Inc. Common Stock

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$2.27

Actual

-$7.50

Surprise

-229.53%

Century Therapeutics, Inc. Common Stock

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.28

Actual

-$0.22

Surprise

+23.88%

Tonix Pharmaceuticals Holding Corp.

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$3.25

Actual

-$3.98

Surprise

-22.32%

Korro Bio, Inc. Common Stock

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$2.10

Actual

-$1.65

Surprise

+21.74%

Verrica Pharmaceuticals Inc. Common Stock

Report Date

Mar 11, 2026 For Q4 25

Estimate

-$0.81

Actual

-$0.46

Surprise

+43.22%

Champions Oncology, Inc.

Report Date

Mar 12, 2026 For Q3 26

Estimate

$0.09

Actual

-$0.02

Surprise

-121.79%

FAQ

What were Ionis Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Ionis Pharmaceuticals, Inc. Common Stock reported EPS of -$1.41, missing estimates by -4.63%, and revenue of $203.00M, 27.5% above expectations.

How did the market react to Ionis Pharmaceuticals, Inc. Common Stock's Q4 2025 earnings?

The stock price moved up 1.06%, changed from $81.36 before the earnings release to $82.22 the day after.

When is Ionis Pharmaceuticals, Inc. Common Stock expected to report next?

The next earning report is scheduled for Apr 28, 2026.

What are the forecasts for Ionis Pharmaceuticals, Inc. Common Stock's next earnings report?

Based on 9 analysts, Ionis Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.88 and revenue of $202.89M for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.